Vincenzo J. Pizzuti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Vincenzo J. Pizzuti has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- You-Yeon Won
Purdue University
6 shared publications Jaewon Lee
Department of Biomedical, Biological and Chemical Engineering, University of Missouri, Columbia, Missouri 65211, United States
4 shared publicationsBennett D. Elzey
Purdue University Center for Cancer Research, West Lafayette, Indiana 47906, United States
3 shared publicationsDhushyanth Viswanath
Davidson School of Chemical Engineering Purdue University West Lafayette Indiana USA
3 shared publicationsMelanie P. Currie
Purdue University Center for Cancer Research, West Lafayette, Indiana 47906, United States
3 shared publicationsSandra E. Torregrosa-Allen
Purdue University Center for Cancer Research, West Lafayette, Indiana 47906, United States
3 shared publications
Latest Publications
- 2 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7418-7428
Second-line CD19 CAR T vs platinum salvage and autologous stem cell transplant for primary mediastinal B-cell lymphoma
Primary mediastinal B-cell lymphoma (PMBCL) is a rare form of large B-cell lymphoma (LBCL), with ∼90% of patients cured with frontline treatment. For relapsed or refractory (R/R) disease, the optimal treatment is unclear. CD19 chimeric antigen receptor T-cell (CAR T) therapy has been established as the preferred second-line (2L) treatment for primary refractory or early-relapsing LBCL based on the overall survival benefits observed in landmark phase 3 trials. However, patients with PMBCL were underrepresented in these pivotal studies. This study evaluated outcomes of 252 patients treated with 2L therapies for R/R PMBCL at 14 US institutions between 2001 and 2025. Platinum-based salvage therapy with intent to proceed to high-dose therapy and autologous stem cell transplant (HDT/ASCT; platinum cohort) and CD19 CAR T therapy (CAR T cohort) were given as 2L therapies in the real-world setting in 157 and 26 patients, respectively. Overall response rate (ORR), complete response (CR) rate, and median progression-free survival (PFS) were significantly higher in the CAR T cohort compared with the platinum cohort (ORR, 91.3% vs 44.2%; P< .001; CR, 65.2% vs 14.7%; P< .001; median PFS, not reached vs 3.5 months; hazard ratio, 0.28; 95% confidence interval, 0.15-0.54; P = .001). No significant difference was observed in overall survival. This study demonstrated the superior response rate and PFS of CD19 CAR T therapy over platinum-based salvage therapy with intent to proceed to HDT/ASCT as 2L treatment for R/R PMBCL.
- 2 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7418-7428
Second-line CD19 CAR T vs platinum salvage and autologous stem cell transplant for primary mediastinal B-cell lymphoma
Primary mediastinal B-cell lymphoma (PMBCL) is a rare form of large B-cell lymphoma (LBCL), with ∼90% of patients cured with frontline treatment. For relapsed or refractory (R/R) disease, the optimal treatment is unclear. CD19 chimeric antigen receptor T-cell (CAR T) therapy has been established as the preferred second-line (2L) treatment for primary refractory or early-relapsing LBCL based on the overall survival benefits observed in landmark phase 3 trials. However, patients with PMBCL were underrepresented in these pivotal studies. This study evaluated outcomes of 252 patients treated with 2L therapies for R/R PMBCL at 14 US institutions between 2001 and 2025. Platinum-based salvage therapy with intent to proceed to high-dose therapy and autologous stem cell transplant (HDT/ASCT; platinum cohort) and CD19 CAR T therapy (CAR T cohort) were given as 2L therapies in the real-world setting in 157 and 26 patients, respectively. Overall response rate (ORR), complete response (CR) rate, and median progression-free survival (PFS) were significantly higher in the CAR T cohort compared with the platinum cohort (ORR, 91.3% vs 44.2%; P< .001; CR, 65.2% vs 14.7%; P< .001; median PFS, not reached vs 3.5 months; hazard ratio, 0.28; 95% confidence interval, 0.15-0.54; P = .001). No significant difference was observed in overall survival. This study demonstrated the superior response rate and PFS of CD19 CAR T therapy over platinum-based salvage therapy with intent to proceed to HDT/ASCT as 2L treatment for R/R PMBCL.
- Open Access
- 28 July 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4)
Longitudinal patient-reported outcomes and quality-of-life trajectories over 2 years in CAR-T therapy recipients
- 28 July 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (4)
Open AccessLongitudinal patient-reported outcomes and quality-of-life trajectories over 2 years in CAR-T therapy recipients
- 25 August 2023
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 16 (1) , e1924
Nanotechnology‐enhanced radiotherapy and the abscopal effect: Current status and challenges of nanomaterial‐based radio‐immunotherapy
Rare but consistent reports of abscopal remission in patients challenge the notion that radiotherapy (RT) is a local treatment; radiation‐induced cancer cell death can trigger activation and recruitment of dendritic cells to the primary tumor site, which subsequently initiates systemic immune responses against metastatic lesions. Although this abscopal effect was initially considered an anomaly, combining RT with immune checkpoint inhibitor therapies has been shown to greatly improve the incidence of abscopal responses via modulation of the immunosuppressive tumor microenvironment. Preclinical studies have demonstrated that nanomaterials can further improve the reliability and potency of the abscopal effect for various different types of cancer by (1) altering the cell death process to be more immunogenic, (2) facilitating the capture and transfer of tumor antigens from the site of cancer cell death to antigen‐presenting cells, and (3) co‐delivering immune checkpoint inhibitors along with radio‐enhancing agents. Several unanswered questions remain concerning the exact mechanisms of action for nanomaterial‐enhanced RT and for its combination with immune checkpoint inhibition and other immunostimulatory treatments in clinically relevant settings. The purpose of this article is to summarize key recent developments in this field and also highlight knowledge gaps that exist in this field. An improved mechanistic understanding will be critical for clinical translation of nanomaterials for advanced radio‐immunotherapy.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
- 25 August 2023
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 16 (1) , e1924
Nanotechnology‐enhanced radiotherapy and the abscopal effect: Current status and challenges of nanomaterial‐based radio‐immunotherapy
Rare but consistent reports of abscopal remission in patients challenge the notion that radiotherapy (RT) is a local treatment; radiation‐induced cancer cell death can trigger activation and recruitment of dendritic cells to the primary tumor site, which subsequently initiates systemic immune responses against metastatic lesions. Although this abscopal effect was initially considered an anomaly, combining RT with immune checkpoint inhibitor therapies has been shown to greatly improve the incidence of abscopal responses via modulation of the immunosuppressive tumor microenvironment. Preclinical studies have demonstrated that nanomaterials can further improve the reliability and potency of the abscopal effect for various different types of cancer by (1) altering the cell death process to be more immunogenic, (2) facilitating the capture and transfer of tumor antigens from the site of cancer cell death to antigen‐presenting cells, and (3) co‐delivering immune checkpoint inhibitors along with radio‐enhancing agents. Several unanswered questions remain concerning the exact mechanisms of action for nanomaterial‐enhanced RT and for its combination with immune checkpoint inhibition and other immunostimulatory treatments in clinically relevant settings. The purpose of this article is to summarize key recent developments in this field and also highlight knowledge gaps that exist in this field. An improved mechanistic understanding will be critical for clinical translation of nanomaterials for advanced radio‐immunotherapy.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
- Open Access
- 1 August 2023
- Published by MDPI AG in Journal of Nanotheranostics
- Vol. 4 (3) , 323-345
An Overview of Nanotherapeutic Drug Delivery Options for the Management of Glioblastoma
Glioblastoma is the most common primary, malignant brain tumor that remains uniformly lethal in nearly all cases as a result of extreme cellular heterogeneity, treatment resistance, and recurrence. A major hurdle in therapeutic delivery to brain tumors is the blood–brain barrier (BBB), which is the tightly regulated vascular barrier between the brain parenchyma and systemic circulation that prevents distribution of otherwise beneficial chemotherapeutics to central nervous system tumors. To overcome the obstacle of drug delivery beyond the BBB, nanoparticle formulations have come to the forefront, having demonstrated success in preclinical observations, but have not translated well into the clinical setting. In summary, this review article discusses brain tumors and challenges for drug delivery caused by the BBB, explores the benefits of nanoparticle formulations for brain tumor delivery, describes the characteristics these formulations possess that make them attractive therapeutic strategies, and provides preclinical examples that implement nanoparticles within glioma treatment regimens. Additionally, we explore the pitfalls associated with clinical translation and conclude with remarks geared toward overcoming these issues.
- 1 August 2023
- Published by MDPI AG in Journal of Nanotheranostics
- Vol. 4 (3) , 323-345
Open AccessAn Overview of Nanotherapeutic Drug Delivery Options for the Management of Glioblastoma
Glioblastoma is the most common primary, malignant brain tumor that remains uniformly lethal in nearly all cases as a result of extreme cellular heterogeneity, treatment resistance, and recurrence. A major hurdle in therapeutic delivery to brain tumors is the blood–brain barrier (BBB), which is the tightly regulated vascular barrier between the brain parenchyma and systemic circulation that prevents distribution of otherwise beneficial chemotherapeutics to central nervous system tumors. To overcome the obstacle of drug delivery beyond the BBB, nanoparticle formulations have come to the forefront, having demonstrated success in preclinical observations, but have not translated well into the clinical setting. In summary, this review article discusses brain tumors and challenges for drug delivery caused by the BBB, explores the benefits of nanoparticle formulations for brain tumor delivery, describes the characteristics these formulations possess that make them attractive therapeutic strategies, and provides preclinical examples that implement nanoparticles within glioma treatment regimens. Additionally, we explore the pitfalls associated with clinical translation and conclude with remarks geared toward overcoming these issues.
- Open Access
- 19 May 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (5) , 756
A Review of Mathematics Determining Solute Uptake at the Blood–Brain Barrier in Normal and Pathological Conditions
The blood–brain barrier (BBB) limits movement of solutes from the lumen of the brain microvascular capillary system into the parenchyma. The unidirectional transfer constant, Kin, is the rate at which transport across the BBB occurs for individual molecules. Single and multiple uptake experiments are available for the determination of Kin for new drug candidates using both intravenous and in situ protocols. Additionally, the single uptake method can be used to determine Kin in heterogeneous pathophysiological conditions such as stroke, brain cancers, and Alzheimer’s disease. In this review, we briefly cover the anatomy and physiology of the BBB, discuss the impact of efflux transporters on solute uptake, and provide an overview of the single-timepoint method for determination of Kin values. Lastly, we compare preclinical Kin experimental results with human parallels.
- 19 May 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (5) , 756
Open AccessA Review of Mathematics Determining Solute Uptake at the Blood–Brain Barrier in Normal and Pathological Conditions
The blood–brain barrier (BBB) limits movement of solutes from the lumen of the brain microvascular capillary system into the parenchyma. The unidirectional transfer constant, Kin, is the rate at which transport across the BBB occurs for individual molecules. Single and multiple uptake experiments are available for the determination of Kin for new drug candidates using both intravenous and in situ protocols. Additionally, the single uptake method can be used to determine Kin in heterogeneous pathophysiological conditions such as stroke, brain cancers, and Alzheimer’s disease. In this review, we briefly cover the anatomy and physiology of the BBB, discuss the impact of efflux transporters on solute uptake, and provide an overview of the single-timepoint method for determination of Kin values. Lastly, we compare preclinical Kin experimental results with human parallels.
- 6 May 2021
- Published by American Chemical Society (ACS) in Industrial & Engineering Chemistry Research
- Vol. 60 (19) , 7081-7096
Pilot-Scale Optimization of the Solvent Exchange Production and Lyophilization Processing of PEG–PLA Block Copolymer-Encapsulated CaWO4 Radioluminescent Nanoparticles for Theranostic Applications
- 6 May 2021
- Published by American Chemical Society (ACS) in Industrial & Engineering Chemistry Research
- Vol. 60 (19) , 7081-7096
Pilot-Scale Optimization of the Solvent Exchange Production and Lyophilization Processing of PEG–PLA Block Copolymer-Encapsulated CaWO4 Radioluminescent Nanoparticles for Theranostic Applications
- 9 July 2020
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 3 (8) , 4858-4872
Bilirubin-Coated Radioluminescent Particles for Radiation-Induced Photodynamic Therapy
Photodynamic therapy (PDT) has shown potential as a cancer treatment modality, but its clinical application is limited due to its visible-light activation since visible wavelengths of light cannot penetrate tissues well. Additionally, combination therapies utilizing PDT and radiotherapy have shown clinical promise in several cancers but are limited again by light penetration and the need for selective photosensitization of the treatment area. Herein, we report the development of bilirubin-photodynamic nanoparticles (PEGylated bilirubin-encapsulated CaWO4 nanoparticles or “PEG-BR/CWO NPs”). PEG-BR/CWO NPs are a formulation of PEGylated bilirubin micelles encapsulating CaWO4 nanoparticles. These particles are capable of activating PDT via X-ray irradiation within deep tissues due to the radioluminescence properties of their CaWO4 nanoparticle cores. PEG-BR/CWO NPs facilitate a combination of photodynamic and radiation therapy and represent a previously unexplored application of PEG-bilirubin conjugates as photosensitizing agents. When irradiated by X-rays, PEG-BR/CWO NPs emit UV-A and visible light from their CaWO4 cores, which excites bilirubin and leads to the production of singlet oxygen. PEG-BR/CWO NPs exhibit improvements over X-ray therapy alone in vitro and in murine xenograft models of head and neck cancer. The data presented in this study indicate that PEG-BR/CWO NPs are promising agents for facilitating combined radio-photodynamic therapy in deep tissue tumors.
- 9 July 2020
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 3 (8) , 4858-4872
Bilirubin-Coated Radioluminescent Particles for Radiation-Induced Photodynamic Therapy
Photodynamic therapy (PDT) has shown potential as a cancer treatment modality, but its clinical application is limited due to its visible-light activation since visible wavelengths of light cannot penetrate tissues well. Additionally, combination therapies utilizing PDT and radiotherapy have shown clinical promise in several cancers but are limited again by light penetration and the need for selective photosensitization of the treatment area. Herein, we report the development of bilirubin-photodynamic nanoparticles (PEGylated bilirubin-encapsulated CaWO4 nanoparticles or “PEG-BR/CWO NPs”). PEG-BR/CWO NPs are a formulation of PEGylated bilirubin micelles encapsulating CaWO4 nanoparticles. These particles are capable of activating PDT via X-ray irradiation within deep tissues due to the radioluminescence properties of their CaWO4 nanoparticle cores. PEG-BR/CWO NPs facilitate a combination of photodynamic and radiation therapy and represent a previously unexplored application of PEG-bilirubin conjugates as photosensitizing agents. When irradiated by X-rays, PEG-BR/CWO NPs emit UV-A and visible light from their CaWO4 cores, which excites bilirubin and leads to the production of singlet oxygen. PEG-BR/CWO NPs exhibit improvements over X-ray therapy alone in vitro and in murine xenograft models of head and neck cancer. The data presented in this study indicate that PEG-BR/CWO NPs are promising agents for facilitating combined radio-photodynamic therapy in deep tissue tumors.
- 12 August 2019
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 5 (9) , 4776-4789
Folic Acid-Conjugated Radioluminescent Calcium Tungstate Nanoparticles as Radio-Sensitizers for Cancer Radiotherapy
Radiation therapy is a primary treatment modality for many forms of cancer. Normally, the highest tolerable dose of ionizing radiation is used to treat tumors, but limitations imposed by normal tissue complications present challenges for local tumor control. In light of this, a class of compounds called radio-sensitizers have been developed to enhance the effectiveness of radiation. Many of these are small molecule drugs found to interact favorably with radiation therapy, but recent advances have been made using nanoparticles as radio-sensitizers. Herein, we report the utilization of radio-luminescent calcium tungstate nanoparticles that emit photoelectrons, UV-A, and visible light during X-ray irradiation, acting as effective radio-sensitizers (“Radio Luminescence Therapy”). In addition, a folic acid-functionalized form of these nanoparticles was shown to enhance radio-sensitization in vitro and in murine models of head and neck cancer. Folic acid-functionalized particles were found to decrease UV-A-induced clonogenic cell survival relative to nonfunctionalized particles. Several possible mechanisms were explored, and the folic acid-functionalized particles were found to mediate this increase in efficacy likely by activating pro-proliferative signaling through folate’s innate mitogenic activity, leading to decreased repair of UV-A-induced DNA lesions. Finally, a clinical case study of a canine sarcoma patient demonstrated the initial safety and feasibility of translating these folic acid-functionalized particles into the clinic as radio-sensitizers in the treatment of spontaneous tumors.
- 12 August 2019
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 5 (9) , 4776-4789
Folic Acid-Conjugated Radioluminescent Calcium Tungstate Nanoparticles as Radio-Sensitizers for Cancer Radiotherapy
Radiation therapy is a primary treatment modality for many forms of cancer. Normally, the highest tolerable dose of ionizing radiation is used to treat tumors, but limitations imposed by normal tissue complications present challenges for local tumor control. In light of this, a class of compounds called radio-sensitizers have been developed to enhance the effectiveness of radiation. Many of these are small molecule drugs found to interact favorably with radiation therapy, but recent advances have been made using nanoparticles as radio-sensitizers. Herein, we report the utilization of radio-luminescent calcium tungstate nanoparticles that emit photoelectrons, UV-A, and visible light during X-ray irradiation, acting as effective radio-sensitizers (“Radio Luminescence Therapy”). In addition, a folic acid-functionalized form of these nanoparticles was shown to enhance radio-sensitization in vitro and in murine models of head and neck cancer. Folic acid-functionalized particles were found to decrease UV-A-induced clonogenic cell survival relative to nonfunctionalized particles. Several possible mechanisms were explored, and the folic acid-functionalized particles were found to mediate this increase in efficacy likely by activating pro-proliferative signaling through folate’s innate mitogenic activity, leading to decreased repair of UV-A-induced DNA lesions. Finally, a clinical case study of a canine sarcoma patient demonstrated the initial safety and feasibility of translating these folic acid-functionalized particles into the clinic as radio-sensitizers in the treatment of spontaneous tumors.
- 1 June 2019
- Published by Elsevier in Journal of Controlled Release
- Vol. 303, 237-252
Radioluminescent nanoparticles for radiation-controlled release of drugs
- 1 June 2019
- Published by Elsevier in Journal of Controlled Release
- Vol. 303, 237-252
Radioluminescent nanoparticles for radiation-controlled release of drugs
- 26 February 2018
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 4 (4) , 1445-1462
PEG–PLA-Coated and Uncoated Radio-Luminescent CaWO4 Micro- and Nanoparticles for Concomitant Radiation and UV-A/Radio-Enhancement Cancer Treatments
Currently, there is great interest in the development of ways to achieve the benefits of radiation treatment with reduced negative effects. The present study demonstrates the utilization of Radio-Luminescent Particles (RLPs) as a means to achieve radio-sensitization/enhancement and their ability to affect head and neck cancer cell cultures (in vitro) and xenografts (in vivo). Our approach utilizes a naturally-abundant radio-luminescent mineral, calcium tungstate (CaWO4) in its micro or nanoparticulate form for generating secondary UV-A light by γ ray/X-ray photons. In vitro tests demonstrate that an un-optimized RLP materials (uncoated CaWO4 (CWO) microparticles (MPs) and PEG-PLA-coated CWO nanoparticles (NPs)) induce a significant enhancement of the tumor suppressive effect of X-rays/γ rays in both radio-sensitive and radio-resistant cancer models; uncoated CWO MPs and PEG-PLA-coated CWO NPs demonstrate comparable radio-sensitization efficacy in vitro. Mechanistic studies reveal that concomitant CaWO4 causes increased mitotic death in radio-resistant cells treated with radiation, whereas CaWO4 sensitizes radio-sensitive cells to X-ray-induced apoptosis/necrosis. Radio-sensitization efficacy of intratumorally injected CaWO4 particles (uncoated CWO MPs and PEG-PLA-coated CWO NPs) is also evaluated in vivo in mouse head and neck cancer xenografts. Uncoated CWO MPs suppress tumor growth more effectively than PEG-PLA-coated CWO NPs. Based on theoretical considerations, an argument is proposed that uncoated CWO MPs release sub-toxic levels of tungstate ions, which cause increased effects of photoelectric electron emissions. The effect of folic acid functionalization on in vitro radio-sensitization behavior produced by PEG-PLA-coated CWO NPs is studied. Surface folic acid results in a significant improvement in radio-sensitization efficiency of CaWO4.
- 26 February 2018
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 4 (4) , 1445-1462
PEG–PLA-Coated and Uncoated Radio-Luminescent CaWO4 Micro- and Nanoparticles for Concomitant Radiation and UV-A/Radio-Enhancement Cancer Treatments
Currently, there is great interest in the development of ways to achieve the benefits of radiation treatment with reduced negative effects. The present study demonstrates the utilization of Radio-Luminescent Particles (RLPs) as a means to achieve radio-sensitization/enhancement and their ability to affect head and neck cancer cell cultures (in vitro) and xenografts (in vivo). Our approach utilizes a naturally-abundant radio-luminescent mineral, calcium tungstate (CaWO4) in its micro or nanoparticulate form for generating secondary UV-A light by γ ray/X-ray photons. In vitro tests demonstrate that an un-optimized RLP materials (uncoated CaWO4 (CWO) microparticles (MPs) and PEG-PLA-coated CWO nanoparticles (NPs)) induce a significant enhancement of the tumor suppressive effect of X-rays/γ rays in both radio-sensitive and radio-resistant cancer models; uncoated CWO MPs and PEG-PLA-coated CWO NPs demonstrate comparable radio-sensitization efficacy in vitro. Mechanistic studies reveal that concomitant CaWO4 causes increased mitotic death in radio-resistant cells treated with radiation, whereas CaWO4 sensitizes radio-sensitive cells to X-ray-induced apoptosis/necrosis. Radio-sensitization efficacy of intratumorally injected CaWO4 particles (uncoated CWO MPs and PEG-PLA-coated CWO NPs) is also evaluated in vivo in mouse head and neck cancer xenografts. Uncoated CWO MPs suppress tumor growth more effectively than PEG-PLA-coated CWO NPs. Based on theoretical considerations, an argument is proposed that uncoated CWO MPs release sub-toxic levels of tungstate ions, which cause increased effects of photoelectric electron emissions. The effect of folic acid functionalization on in vitro radio-sensitization behavior produced by PEG-PLA-coated CWO NPs is studied. Surface folic acid results in a significant improvement in radio-sensitization efficiency of CaWO4.